Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Bempedoic Acid in Clinical Practice
Christie M. Ballantyne, Harold Bays, Alberico L. Catapano, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 35, Iss. 4, pp. 853-864
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

A Modern Approach to Dyslipidemia
Amanda J. Berberich, Robert A. Hegele
Endocrine Reviews (2021) Vol. 43, Iss. 4, pp. 611-653
Open Access | Times Cited: 299
Dyslipidemia and Cardiovascular Disease: Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies
Zhiyong Du, Yanwen Qin
Journal of Clinical Medicine (2023) Vol. 12, Iss. 1, pp. 363-363
Open Access | Times Cited: 48
Lipid Lowering Therapy: An Era Beyond Statins
Toufik Abdul‐Rahman, Syed Muhammad Awais Bukhari, Emiliano Cantu‐Herrera, et al.
Current Problems in Cardiology (2022) Vol. 47, Iss. 12, pp. 101342-101342
Closed Access | Times Cited: 55
Existing and emerging strategies to lower Lipoprotein(a)
Gregory G. Schwartz, Christie M. Ballantyne
Atherosclerosis (2022) Vol. 349, pp. 110-122
Open Access | Times Cited: 51
Bempedoic Acid: for Whom and When
Massimiliano Ruscica, Cesare R. Sirtori, Stefano Carugo, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 10, pp. 791-801
Open Access | Times Cited: 51
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Anna Martin, Sonja Lang, Tobias Goeser, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 533-546
Open Access | Times Cited: 50
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)
Christie M. Ballantyne, Maciej Banach, Harold Bays, et al.
The American Journal of Cardiology (2022) Vol. 174, pp. 1-11
Open Access | Times Cited: 46
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Gianni Biolo, Pierandrea Vinci, Alessandro Mangogna, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 41
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi, Manuela Casula, Arrigo F.G. Cicero, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108507-108507
Open Access | Times Cited: 34
The lipogenic enzyme acetoacetyl-CoA synthetase and ketone body utilization for denovo lipid synthesis, a review
James D. Bergstrom
Journal of Lipid Research (2023) Vol. 64, Iss. 8, pp. 100407-100407
Open Access | Times Cited: 23
Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia
Shirin Ibrahim, Laurens F. Reeskamp, Jim N. de Goeij, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 7, pp. 892-900
Open Access | Times Cited: 11
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins
Maurizio Capuozzo, Alessandro Ottaiano, Claudia Cinque, et al.
Hipertensión y Riesgo Vascular (2025)
Closed Access | Times Cited: 1
Lipids dysregulation in diseases: core concepts, targets and treatment strategies
Tikam Chand Dakal, Feng Xiao, Chandra Kanta Bhusal, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
New Therapies for Primary Hyperlipidemia
Carlos A. Aguilar‐Salinas, Rita A. Gómez‐Díaz, Pablo Corral
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 5, pp. 1216-1224
Open Access | Times Cited: 45
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Ramyashree Tummala, Manasvi Gupta, Arvind Reddy Devanabanda, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 1287-1296
Open Access | Times Cited: 33
Revisiting secondary prevention in coronary heart disease
Alben Sigamani, Rajeev Gupta
Indian Heart Journal (2022) Vol. 74, Iss. 6, pp. 431-440
Open Access | Times Cited: 29
Regulation of protein prenylation
Dominik Jung, Hagen S. Bachmann
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114915-114915
Open Access | Times Cited: 21
Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
Giosiana Bosco, Francesco Barbagallo, Salvatore Spampinato, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2444-2444
Open Access | Times Cited: 20
Advances in Treatment of Dyslipidemia
Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13288-13288
Open Access | Times Cited: 20
Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition
Freddy Duarte Lau, Robert P. Giugliano
JAMA Cardiology (2023) Vol. 8, Iss. 9, pp. 879-879
Closed Access | Times Cited: 17
Italian Association of Hospital Cardiologists Position Paper ‘Gender discrepancy: time to implement gender-based clinical management’
Fabiana Lucà, Daniela Pavan, Michele Massimo Gulizia, et al.
European Heart Journal Supplements (2024) Vol. 26, Iss. Supplement_2, pp. ii264-ii293
Open Access | Times Cited: 6
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Seema Abbasi, Adnan Khan, Muhammad W. Choudhry
Cureus (2024)
Open Access | Times Cited: 6
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Georgios Tsioulos, Dimitris Kounatidis, Natalia G. Vallianou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3537-3537
Open Access | Times Cited: 5
Animal-based evidence supports the influence of biogenic silver and gold nanomaterials on the serum lipid profile: A novel approach in antihyperlipidemia management
Hamed Barabadi, Maha Soltani, Hesam Noqani, et al.
Results in Surfaces and Interfaces (2024) Vol. 16, pp. 100264-100264
Open Access | Times Cited: 5
Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
Akshyaya Pradhan, Monika Bhandari, Pravesh Vishwakarma, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 5, pp. 195-195
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top